Danaher Corporation (NYSE:DHR) delivered third-quarter results that came in stronger than expected, but issued a cautious full-year profit forecast that slightly undershot Wall Street’s estimates at the midpoint.
The stock slipped about 1% in premarket trading as of 10:14 GMT.
For the quarter, the life sciences group reported earnings per share of $1.89, comfortably beating analysts’ expectations of $1.72. Revenue reached $6.05 billion, just above the $6 billion consensus forecast.
“We are encouraged by our third quarter results,” said Rainer Blair, President and CEO of Danaher. “DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings and cash flow expectations.”
Looking ahead, Danaher guided full-year 2025 earnings per share to a range of $7.70 to $7.80. The midpoint of this range came in just below the $7.78 analysts had projected.
The company added that it expects non-GAAP core revenue to increase at a low single-digit pace year-over-year, reflecting a more measured growth outlook in the current market environment.